JP2012505227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505227A5 JP2012505227A5 JP2011531146A JP2011531146A JP2012505227A5 JP 2012505227 A5 JP2012505227 A5 JP 2012505227A5 JP 2011531146 A JP2011531146 A JP 2011531146A JP 2011531146 A JP2011531146 A JP 2011531146A JP 2012505227 A5 JP2012505227 A5 JP 2012505227A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- agent
- antagonist
- osteoporosis
- produced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 22
- 239000005557 antagonist Substances 0.000 claims 14
- 208000001132 Osteoporosis Diseases 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 108090000681 interleukin 20 Proteins 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 210000004408 hybridoma Anatomy 0.000 claims 5
- 108010008165 Etanercept Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010030247 Oestrogen deficiency Diseases 0.000 claims 2
- 108700012920 TNF Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 claims 1
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 claims 1
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 claims 1
- 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 claims 1
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 108010027445 interleukin-22 receptor Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/246,715 US7837994B2 (en) | 2008-10-07 | 2008-10-07 | Use of anti-IL-20 antibody for treating osteoporosis |
| US12/246,715 | 2008-10-07 | ||
| US23866109P | 2009-08-31 | 2009-08-31 | |
| US61/238,661 | 2009-08-31 | ||
| PCT/US2009/059865 WO2010042634A1 (en) | 2008-10-07 | 2009-10-07 | Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214727A Division JP2016041730A (ja) | 2008-10-07 | 2015-10-30 | リウマチ性関節炎の治療のためのｉｌ−２０アンタゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505227A JP2012505227A (ja) | 2012-03-01 |
| JP2012505227A5 true JP2012505227A5 (enExample) | 2012-11-22 |
| JP5860699B2 JP5860699B2 (ja) | 2016-02-16 |
Family
ID=42100943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531146A Expired - Fee Related JP5860699B2 (ja) | 2008-10-07 | 2009-10-07 | 骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用 |
| JP2015214727A Pending JP2016041730A (ja) | 2008-10-07 | 2015-10-30 | リウマチ性関節炎の治療のためのｉｌ−２０アンタゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214727A Pending JP2016041730A (ja) | 2008-10-07 | 2015-10-30 | リウマチ性関節炎の治療のためのｉｌ−２０アンタゴニストの使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2340039B1 (enExample) |
| JP (2) | JP5860699B2 (enExample) |
| KR (1) | KR101691534B1 (enExample) |
| CN (1) | CN102281898B (enExample) |
| CA (1) | CA2739794A1 (enExample) |
| DK (1) | DK2340039T3 (enExample) |
| WO (1) | WO2010042634A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2558125A4 (en) * | 2010-04-16 | 2013-10-02 | Univ Nat Cheng Kung | TREATMENT OF ILLICITIES ASSOCIATED WITH THE IL-20 RECEPTOR-SIGNALING PATH THROUGH BLOCKING OF IL-20 RECEPTOR ACTIVITY |
| WO2014006230A1 (en) | 2012-07-06 | 2014-01-09 | Novo Nordisk A/S | Il-20 epitopes and il-20 ligands |
| CA2878825A1 (en) * | 2012-07-10 | 2014-01-16 | The Uab Research Foundation | Compositions and methods for modulation of il-20 family cytokine activity |
| US8603470B1 (en) * | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US9376490B2 (en) * | 2014-04-01 | 2016-06-28 | National Cheng Kung University | Treatment of inflammatory pain using IL-20 antagonists |
| CN107249630A (zh) * | 2014-11-24 | 2017-10-13 | 国家健康与医学研究院 | 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重 |
| US9982043B2 (en) | 2016-06-03 | 2018-05-29 | National Cheng Kung University | Use of IL-20 antagonists for treating pancreatic cancer |
| KR101796025B1 (ko) | 2017-04-25 | 2017-11-10 | 가톨릭대학교 산학협력단 | 사포그릴레이트, 프라바스타틴 및 tnf-억제제를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US6649779B2 (en) * | 1997-05-02 | 2003-11-18 | Wyeth | Estrenes |
| WO1999027103A1 (en) * | 1997-11-26 | 1999-06-03 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EP1246846B1 (en) * | 1999-12-23 | 2008-09-10 | ZymoGenetics, Inc. | Soluble interleukin-20 receptor |
| DE60043957D1 (de) * | 1999-12-23 | 2010-04-15 | Zymogenetics Inc | Verfahren zur Behandlung von Entzündungen |
| US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| US7122632B2 (en) * | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
| US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| EP1429779A2 (en) * | 2001-09-21 | 2004-06-23 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| CA2465499A1 (en) * | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| US7435800B2 (en) * | 2003-05-23 | 2008-10-14 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
| EP1692180B1 (en) * | 2003-11-21 | 2009-11-04 | ZymoGenetics, Inc. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
| WO2007116818A1 (ja) * | 2006-03-30 | 2007-10-18 | Toray Industries, Inc. | 樹状ポリエステル、その製造方法および熱可塑性樹脂組成物 |
| WO2008016134A1 (fr) * | 2006-08-04 | 2008-02-07 | Norihiro Nishimoto | PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde |
-
2009
- 2009-10-07 CN CN200980140331.2A patent/CN102281898B/zh not_active Expired - Fee Related
- 2009-10-07 DK DK09819827.8T patent/DK2340039T3/en active
- 2009-10-07 CA CA2739794A patent/CA2739794A1/en not_active Abandoned
- 2009-10-07 JP JP2011531146A patent/JP5860699B2/ja not_active Expired - Fee Related
- 2009-10-07 EP EP09819827.8A patent/EP2340039B1/en not_active Not-in-force
- 2009-10-07 KR KR1020117009475A patent/KR101691534B1/ko not_active Expired - Fee Related
- 2009-10-07 WO PCT/US2009/059865 patent/WO2010042634A1/en not_active Ceased
-
2015
- 2015-10-30 JP JP2015214727A patent/JP2016041730A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505227A5 (enExample) | ||
| US11639388B2 (en) | CD3 antigen binding fragment and application thereof | |
| US8426562B2 (en) | Methods and compositions for modulating tumor cell activity | |
| JP2018506961A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2009529920A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2018519364A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JPWO2019129221A5 (enExample) | ||
| JP2012525854A5 (enExample) | ||
| JP2013519367A5 (enExample) | ||
| JP2007510664A5 (enExample) | ||
| JP2007526908A5 (enExample) | ||
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JP2019512523A5 (enExample) | ||
| TW202300527A (zh) | 使用ｇｒｅｍ１拮抗劑治療疾病的方法 | |
| WO2019172165A1 (ja) | 異所性骨化の治療又は予防のための医薬組成物 | |
| KR20210138674A (ko) | Tsg-6 항체 및 그 용도 | |
| CN116284426A (zh) | 一种抗gucy2c/cd3双特异性抗体及其用途 | |
| CN114729036A (zh) | 抗干细胞因子抗体及其使用方法 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| TWI890011B (zh) | 藉由靶向細胞外α-烯醇化酶調節醣酵解以治療人類疾病的方法 |